Compare IIPR & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIPR | OGN |
|---|---|---|
| Founded | 2016 | 1923 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | IIPR | OGN |
|---|---|---|
| Price | $50.97 | $8.83 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $45.00 | $11.75 |
| AVG Volume (30 Days) | 242.3K | ★ 3.6M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 15.18% | 1.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $2.69 | $0.42 |
| Revenue Next Year | $3.80 | $1.67 |
| P/E Ratio | $10.92 | ★ $9.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.58 | $5.69 |
| 52 Week High | $59.83 | $13.25 |
| Indicator | IIPR | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 74.83 |
| Support Level | $48.01 | $8.32 |
| Resistance Level | $51.68 | $9.79 |
| Average True Range (ATR) | 1.38 | 0.42 |
| MACD | -0.21 | 0.26 |
| Stochastic Oscillator | 48.68 | 96.82 |
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.